Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 18 of the 39 sources its claims cite were checked for support.
Abstract
In Candida albicans , Upc2 is a zinc-cluster transcription factor that targets genes, including those of the ergosterol biosynthesis pathway. To date, three documented UPC2 gain-of-function (GOF) mutations have been recovered from fluconazole-resistant clinical isolates that contribute to an increase in ERG11 expression and decreased fluconazole susceptibility. In a group of 63 isolates with reduced susceptibility to fluconazole, we found that 47 overexpressed ERG11 by at least 2-fold over the average expression levels in 3 unrelated fluconazole-susceptible strains. Of those 47 isolates, 29 contained a mutation in UPC2 , whereas the remaining 18 isolates did not. Among the isolates containing mutations in UPC2 , we recovered eight distinct mutations resulting in putative single amino acid substitutions: G648D, G648S, A643T, A643V, Y642F, G304R, A646V, and W478C. Seven of these resulted in increased ERG11 expression, increased cellular ergosterol, and decreased susceptibility to fluconazole compared to the results for the wild-type strain. Genome-wide transcriptional analysis was performed for the four strongest Upc2 amino acid substitutions (A643V, G648D, G648S, and Y642F). Genes commonly upregulated by all four mutations included those involved in ergosterol biosynthesis, in oxidoreductase activity, the major facilitator efflux pump encoded by the MDR1 gene, and the uncharacterized ATP binding cassette transporter CDR11 . These findings demonstrate that gain-of-function mutations in UPC2 are more prevalent among clinical isolates than previously thought and make a significant contribution to azole antifungal resistance, but the findings do not account for ERG11 overexpression in all such isolates of C. albicans .
Overview
CoChat Summary
TL;DR
In a collection of azole-resistant *Candida albicans* clinical isolates, *ERG11* overexpression was common, and many such isolates carried gain-of-function mutations in *UPC2*. Seven of eight recovered Upc2 substitutions increased *ERG11* expression, cellular ergosterol, and resistance to fluconazole and other ergosterol biosynthesis inhibitors, but *UPC2* mutations did not explain all *ERG11* overexpression.
Key findings
- Among 63 isolates with reduced fluconazole susceptibility, 47 overexpressed *ERG11* by at least 2-fold; 29 of those 47 had a *UPC2* mutation, while 18 did not.
- Eight distinct putative Upc2 amino acid substitutions were recovered: G648D, G648S, A643T, A643V, Y642F, G304R, A646V, and W478C; seven increased *ERG11* expression, increased cellular ergosterol, and decreased fluconazole susceptibility, whereas G304R did not.
- In constructed strains, homozygous mutant *UPC2* alleles generally produced stronger *ERG11* expression and lower azole susceptibility than heterozygous strains; G648D gave the highest *ERG11* expression.
- Microarray analysis of four strong *UPC2* GOF alleles (A643V, G648D, G648S, Y642F) found 61 commonly upregulated and 5 commonly downregulated genes, including ergosterol biosynthesis genes, oxidoreductase genes, *MDR1*, and *CDR11*.
Methods
- Used 72 unrelated clinical *C. albicans* isolates from the University of Iowa, including oral and nonoral sources; fluconazole resistance was defined as MIC ≥ 16 µg/ml, and *ERG11*, *CDR1*, *CDR2*, and *MDR1* expression was measured by qRT-PCR.
- Sequenced *UPC2* alleles from isolates overexpressing *ERG11*, then constructed *C. albicans* strains expressing mutant *UPC2* alleles alone, as heterozygotes with wild-type *UPC2*, and as homozygotes using the SAT1-flipper system.
- Measured antifungal MICs by modified CLSI broth microdilution and Etest, quantified cellular ergosterol spectrophotometrically, and performed genome-wide transcriptional profiling with Affymetrix *C. albicans* custom expression arrays.
Limitations
- The paper states that it cannot define the clinical implications of fluconazole resistance among nonoral isolates, that *ERG11* expression levels in clinical isolates did not always match those in laboratory strains constructed with the same *UPC2* allele, and that not all *ERG11* overexpression was explained by *UPC2* GOF mutations.
- The paper states that other regulators of ergosterol biosynthesis, *UPC2* promoter mutation, *UPC2* duplication, trans-acting mutations, or aneuploidy such as chromosome 5 duplication/chr5L isochromosome may contribute, and that combinatorial effects of activated *UPC2* with mutant *ERG11* alleles were not explored.
- Evident from the text: most mechanistic work used laboratory-constructed strains rather than the original clinical isolates, so the direct clinical impact of each individual *UPC2* allele remains inferential.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 2 Not valid · 10 Not checked · 90 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In Candida albicans , Upc2 is a zinc-cluster transcription factor that targets genes, including those of the ergosterol biosynthesis pathway.”
- Also stated in: § Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans · boosted
“Alternately, the zinc-cluster transcription factor Upc2 has been shown to regulate the expression of ERG11 and other genes involved in ergosterol biosynthesis (19, 30).”
What the sources say
- Supportedcites [19] 19. MacPherson S, et al. 2005. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob. Agents Chemother. 49 :1745-1752. source
The Results identify C. albicans Upc2p as a member of the zinc-cluster family of transcriptional regulators. The Results and Discussion report its binding to an ERG2 promoter element and its role in regulating ergosterol-biosynthesis genes. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [30] 30. Silver PM, Oliver BG, White TC. 2004. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot. Cell 3 :1391-1397. source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans · boosted
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“As seen with TAC1 or MRR1 mutations, a loss-of-heterozygosity event that results in two GOF alleles, either by a mitotic recombination event between homologous chromosomes or by a loss of a chromosome combined with a duplication of the homologous chromosome, would provide an advantage when challenged with antifungals (2, 22).”
What the sources say
- Not checked — no full text of the sourcecites [2] 2. Coste AT, et al. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172 :2139-2156. source
- Supportedcites [22] 22. Morschhauser J, et al. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3 :e164. doi:10.1371/journal.ppat.0030164. source
The Discussion states that two mutated MRR1 alleles produce greater drug resistance than one and that this advantage during antimycotic therapy can select for loss of heterozygosity. It also names mitotic recombination and chromosome loss followed by duplication as routes to that loss. This paper supports the MRR1 portion of the sentence; the TAC1 example has a separate citation. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of those isolates that did overexpress MDR1 , even fewer isolates expressed MDR1 to the levels previously observed in azole-resistant isolates (22).”
What the sources say
- Supportedcites [22] 22. Morschhauser J, et al. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3 :e164. doi:10.1371/journal.ppat.0030164. source
The citation supports the benchmark of MDR1 overexpression in azole-resistant isolates, not the citing authors’ count of how many of their isolates reached it. In the Results section on MRR1 and MDR1 expression (page not provided), the source reports MDR1 overexpression in fluconazole-resistant clinical isolates F5, G5, and 6692 relative to susceptible isolates. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“ERG11 is transcriptionally regulated by the zinc cluster transcription factor Upc2.”
What the sources say
- Partly supportedcites [4] 4. Crowley JH, Leak FW, Jr, Shianna KV, Tove S, Parks LW. 1998. A mutation in a purported regulatory gene affects control of sterol uptake in Saccharomyces cerevisiae. J. Bacteriol. 180 :4177-4183. sourceExperimental — accuracy not yet measured
The Abstract identifies UPC2 as a gene encoding a protein with a Zn(II)2Cys6 DNA-binding motif, and the Discussion describes it as a predicted member of that regulatory protein family. Neither passage establishes that Upc2 transcriptionally regulates ERG11; a search for ERG11 found no passage addressing that relationship. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As has been previously observed in UPC2 GOF mutations, aminoacidsubstitutions resulting from activating mutations were localized near the C terminus, where the activation domain of zinc-cluster transcription factors is found (18).”
What the sources say
- Supportedcites [18] 18. MacPherson S, Larochelle M, Turcotte B. 2006. A fungal family of transcriptional regulators: the zinc cluster proteins. Microbiol. Mol. Biol. Rev. 70 :583-604. source
The Introduction states that the activation domain is most often C-terminal and identifies a gain-of-function UPC2 mutation, Gly888Asp, within that domain. It also reports gain-of-function mutations in the activation domains of other zinc-cluster proteins. The paper describes one specific UPC2 mutation, rather than multiple UPC2 substitutions. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
61 more claims
Create a free account to see all 116 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 31
- It may state two separate claims as one. 27
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many ERG11 mutations seem to interfere with drug binding and to decrease susceptibility in an additive manner36.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CaUpc2, the primary transcriptional activator of CaERG11 and other ergosterol biosynthetic pathway genes [16].”
From The Candida glabrata Upc2A transcription factor is a global regulator of antifungal drug resistance pathways (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meanwhile, mutations in this pathway, causing alterations in enzymes activity or drug binding sites, are major factors which are related with azole resistance.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the ERG11 and ERG3 genes or the UPC2 gene which encodes a transcription factor contribute to azole resistance.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast, gain-of-function mutations in UPC2 often lead to high expression of ERG11 and make a signi fi cant contribution to azole resistance.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [46]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ RESULTS
“From our collection of 72 isolates, 9 were classified as fluconazole susceptible, while the remaining isolates were resistant.”
§ MATERIALS AND METHODS
“| 1-10 | N/A | Azole susceptible | University of Iowa | | 11-72 | N/A | Azole resistant | University of Iowa |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ MATERIALS AND METHODS
“pUPC2-W467C”
§ MATERIALS AND METHODS
“| 25B2D1 | UPC2M4A | UPC2 W478C ::FRT/ UPC2 W478C ::FRT | This study |”
Citations
Cites
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353 · cited 1×
“albicans by the interplay of several mechanisms of resistance (17, 21, 23, 32).”
BackgroundA rapid and simple method for preparation of RNA from Saccharomyces cerevisiae
Schmitt, M. E., Brown, T. A., & Trumpower, B. L. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.10.3091 · Cited by 1,338
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Klein, R. S., Harris, C. A., Small, C. B., Moll, B., Lesser, M., & Friedland, G. H. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408093110602 · Cited by 863 · cited 2×
“Candida albicans is an opportunistic fungal pathogen thatcauses mucosal, cutaneous, and systemic infections, including oropharyngeal candidiasis (OPC), the most frequent infection in people with AIDS (9, 13).”
BackgroundSanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 1×
“Overexpression of the efflux transporter genes CDR1, CDR2, and MDR1 is a common mechanism of drug resistance in this organism (10, 17, 26).”
BackgroundThe SAT1 flipper, an optimized tool for gene disruption in Candida albicans
Reuß, O., Vik, Å., Kolter, R., & Morschhäuser, J. (2004) · Gene · doi:10.1016/j.gene.2004.06.021 · Cited by 742 · cited 4×
“For selection of strains containing the SAT1-flipper cassette (25), nourseothricin (200 g/ ml) was added to YPD agar plates.”
BackgroundMethodInfluentialSelf-citationAneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2006) · Science · doi:10.1126/science.1128242 · Cited by 733 · cited 1×
“ERG11 gene amplification by chromosome 5 duplication or the presence of a chr5L isochromosome is known to contribute to azole resistance (29).”
BackgroundA Fungal Family of Transcriptional Regulators: the Zinc Cluster Proteins
MacPherson, S., Larochelle, M., & Turcotte, B. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00015-06 · Cited by 612 · cited 1×
“As has been previously observed in UPC2 GOF mutations, amino acid substitutions resulting from activating mutations were localized near the C terminus, where the activation domain of zinc-cluster transcription factors is found (18).”
BackgroundAntifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Cited by
Items 101–200 of 243
Disruption of Membrane Integrity by the Bacterium-Derived Antifungal Jagaricin
Fischer, D., Geßner, G., Fill, T. P., Barnett, R., Tron, K., Dornblut, K., Kloß, F., Stallforth, P., Hube, B., Heinemann, S. H., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00707-19 · Cited by 25
Zhang, M.-R., Zhao, F., Wang, S., Lv, S., Mou, Y., Yao, C.-L., Zhou, Y., & Li, F.-Q. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-4856-8 · Cited by 26
Antifungal adjuvants: Preserving and extending the antifungal arsenal
Butts, A., Palmer, G. E., & Rogers, P. D. (2017) · Virulence · doi:10.1080/21505594.2016.1216283 · Cited by 26
“drug resistant isolates are Cdr1 and Cdr2 while overexpression of the MFS transporter Mdr1 appear to be less prevalent.(76) These pumps have varying substrate specificities and limited structural similarities, so it is not surprising that inhibitors are rarely active against both classes.”
BackgroundSelf-citationNishimoto, A. T., Zhang, Q., Hazlett, B., Morschhäuser, J., & Rogers, P. D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00078-19 · Cited by 24
“albicans clinical isolates (including 10 fluconazole-susceptible and 57 fluconazole-resistant isolates) that we had previously described (20, 29).”
BackgroundMethodResultSelf-citationMaenchantrarath, C., Khumdee, P., Samosornsuk, S., Mungkornkaew, N., & Samosornsuk, W. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02564-4 · Cited by 27
“Contrarily, MDR1 gene does not possess the DRE element, but also MDR1 promoter does not directly react towards fluconazole [13].”
BackgroundInduction of Candida albicans Drug Resistance Genes by Hybrid Zinc Cluster Transcription Factors
Schneider, S., & Morschhäuser, J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04448-14 · Cited by 23
Self-citationThe Microevolution of Antifungal Drug Resistance in Pathogenic Fungi
Boyce, K. J. (2023) · Microorganisms · doi:10.3390/microorganisms11112757 · Cited by 29
Woods, K., & Höfken, T. (2016) · Molecular Microbiology · doi:10.1111/mmi.13244 · Cited by 23
“Several gain-of-function mutants of UPC2 have been identified from azole-resistant clinical isolates (Dunkel et al., 2008; Heilmann et al., 2010; Hoot et al., 2011; Flowers et al., 2012).”
BackgroundDoorley, L. A., Barker, K. S., Zhang, Q., Rybak, J. M., & Rogers, P. D. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.08.030 · Cited by 24
Self-citationSitterlé, E., Coste, A. T., Obadia, T., Maufrais, C., Chauvel, M., Sertour, N., Sanglard, D., Puel, A., d’Enfert, C., & Bougnoux, M. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz537 · Cited by 27
Shrivastava, M., Kouyoumdjian, G. S., Kirbizakis, E., Ruiz, D., Henry, M., Vincent, A. T., Sellam, A., & Whiteway, M. S. (2023) · mBio · doi:10.1128/mbio.01807-23 · Cited by 24
“One of the common approaches to investigating the regulatory networks controlling drug resistance in fungal pathogens is through comparison with the S. cerevisiae circuits; this approach has led to the discovery of many TFs responsible for drug resistance in both S. cerevisiae and C. albicans , including Fcr1, Ndt80,…”
BackgroundVan Hauwenhuyse, F., Fiori, A., & Van Dijck, P. (2014) · Eukaryotic Cell · doi:10.1128/ec.00096-14 · Cited by 20
Candida auris: The Canary in the Mine of Antifungal Drug Resistance
Montoya, M. C., Moye-Rowley, W. S., & Krysan, D. J. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00239 · Cited by 21
Overexpression approaches to advance understanding of Candida albicans
Rai, L. S., van Wijlick, L., Chauvel, M., d’Enfert, C., Legrand, M., & Bachellier‐Bassi, S. (2021) · Molecular Microbiology · doi:10.1111/mmi.14818 · Cited by 20
Antifungal resistance, combinations and pipeline: oh my!
Stover, K. R., Hawkins, B. K., Keck, J. M., Barber, K. E., & Cretella, D. A. (2023) · Drugs in Context · doi:10.7573/dic.2023-7-1 · Cited by 22
Zande, P. V., Gautier, C., Kawar, N., Maufrais, C., Metzner, K., Wash, E., Beach, A. K., Bracken, R., Maciel, E. I., de Sá, N. P., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012497 · Cited by 23
The Ins and Outs of Azole Antifungal Drug Resistance: Molecular Mechanisms of Transport
Zavřel, M., Esquivel, B. D., & White, T. C. (2017) · Springer eBooks · doi:10.1007/978-1-4939-0694-9_29 · Cited by 24
“(Dunkel et al. 2008a; Flowers et al. 2012; Heilmann et al. 2010; Hoot et al. 2011).”
BackgroundWu, Y., Li, C., Wang, Z., Gao, J., Tang, Z., Chen, H., & Ying, C. (2018) · Medical Mycology · doi:10.1093/mmy/myx099 · Cited by 19
Zhang, M., Dong, P., Eldesouky, H. E., Zhan, Y., Lin, H., Wang, Z., Salama, E. A., Jusuf, S., Zong, C., Chen, Z., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c00900 · Cited by 21
Romo, J. A., Pierce, C. G., Esqueda, M., Hung, C.-Y., Saville, S. P., & Lopez-Ribot, J. L. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00227 · Cited by 20
“albicans gain of function strains in key transcriptional activators of ergosterol biosynthesis and efflux pumps, all of which are resistant to azole antifungals (Schubert et al., 2008; Flowers et al., 2012).”
BackgroundInfluentialRamírez-Zavala, B., Manz, H., Englert, F., Rogers, P. D., & Morschhäuser, J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01655-18 · Cited by 20
Self-citationPotent Synergy between Spirocyclic Pyrrolidinoindolinones and Fluconazole against Candida albicans
Premachandra, I. D. U. A., Scott, K. A., Shen, C., Wang, F., Lane, S., Liu, H., & Vranken, D. L. V. (2015) · ChemMedChem · doi:10.1002/cmdc.201500271 · Cited by 19
Bergin, S. A., Doorley, L. A., Rybak, J. M., Wolfe, K. H., Butler, G., Cuomo, C. A., & Rogers, P. D. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01619-23 · Cited by 24
“Overexpression of ERG11 , often by gain-of-function mutations in the transcriptional regulator UPC2 , has been implicated in resistance in C. albicans (30–32).”
Self-citationWang, X., Liu, J., Chen, J., Zhang, M., Tian, C., Peng, X.-P., Li, G., Chang, W., & Lou, H. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104771 · Cited by 18
Yin, Y., Zhang, H., Zhang, Y., Hu, C., Sun, X., Liu, W. Y., & Li, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01316-20 · Cited by 17
Chauhan, A., Carolus, H., Sofras, D., Kumar, M., Kumar, P., Nair, R., Narayanan, A., Yadav, K., Ali, B., Biriukov, V., et al. (2025) · Molecular Microbiology · doi:10.1111/mmi.15379 · Cited by 16
“1-adapted strain, the one in the UPC2 gene, which encodes a transcription factor, looked interesting as this mutation, UPC2 S332R , is upstream of the hotspot of gain- of-function mutations (Flowers et al. 2012) and has not been reported previously.”
Liu, Z., Yang, H., Huang, R., Li, X., Sun, T., & Zhu, L. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00284-24 · Cited by 23
“In addition, ERG11 amplification, driven by transcription factors such as Upc2, counteracts the effects of azoles, further promoting resistance (118, 119).”
Zhou, X., Hilk, A. L., Solis, N. V., de Sá, N. P., Hogan, B. M., Bierbaum, T. A., Poeta, M. D., Filler, S. G., Burrack, L. S., & Selmecki, A. M. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012389 · Cited by 20
“Point mutations in ergos-terol-related genes like ERG11 and UPC2 that cause drug resistance in Candida species are frequently homozygous in diploid organisms and result in higher MIC than heterozygous mutations [84–89].”
BackgroundPais, P., Galocha, M., Takahashi‐Nakaguchi, A., Chibana, H., & Teixeira, M. C. (2022) · Microbial Cell · doi:10.15698/mic2022.11.786 · Cited by 19
“albicans [29]; here we show that Upc2A variants can also be acquired in vivo by azole FIGURE 2: Impact analysis of genomic variants found exclusively in the genomes of resistant isolates.”
BackgroundTaylor, M. B., Skophammer, R. G., Warwick, A. R., Geck, R. C., Boyer, J. M., Students, Y., Walson, M., Large, C. R. L., Hickey, A. S.-M., Rowley, P. A., et al. (2022) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkac246 · Cited by 15
Zare‐Khafri, M., Alizadeh, F., Nouripour‐Sisakht, S., Khodavandi, A., & Gerami, M. (2020) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2019.0354 · Cited by 18
Kim, D., Shin, Y., Lee, S., Wimonmuang, K., Kang, K. B., Lee, Y., & Yun, S. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.15305 · Cited by 12
Vandecruys, P., Baldewijns, S., Sillen, M., Genechten, W. V., & Dijck, P. V. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2233696 · Cited by 18
“G648D, G648S, A643T, A643V, Y642F, or G304R, can cause constitutive overexpression of Erg11, and concomitant azole resistance [80].”
BackgroundBhattacharya, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819990-9.00070-6 · Cited by 18
Manganese homeostasis modulates fungal virulence and stress tolerance in Candida albicans
Henry, M., Khemiri, I., Tebbji, F., Abu‐Helu, R., Vincent, A. T., & Sellam, A. (2024) · mSphere · doi:10.1128/msphere.00804-23 · Cited by 17
“Second, as the cellular content of ergosterol is associated with azole sensitivity (47), we tested the impact of Mn availability and smf12 mutation on the abundance of this fungal sterol.”
BackgroundAmann, V., Kissmann, A., Mildenberger, V., Krebs, I., Perez‐Erviti, J. A., Martell-Huguet, E. M., Otero‐González, A. J., Morales-Vicente, F., Rodríguez-Castaño, G. P., Firacative, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129788 · Cited by 13
“For instance, several mutations were associated with an increased expression of ERG11 as well as an increased ergosterol production [26].”
BackgroundBencova, A., Goffa, E., Morvová, M., Valachovič, M., Griač, P., Hervay, N. T., & Gbelská, Y. (2020) · Mycopathologia · doi:10.1007/s11046-020-00459-4 · Cited by 12
Gallo-Ebert, C., Donigan, M., Liu, H.-Y., Pascual, F., Manners, M., Pandya, D., Swanson, R., Gallagher, D., Chen, W., Carman, G. M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.526087 · Cited by 11
Machine Learning for Antimicrobial Resistance Research and Drug Development
Shankarnarayan, S. A., Guthrie, J. D., & Charlebois, D. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104841 · Cited by 13
The hidden threat: Unveiling the rise of antifungal drug resistance
Chaudhary, R., & Thakur, Z. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.108068 · Cited by 12
Jahanshiri, Z., Manifar, S., Arastehnazar, F., Hatami, F., & Lotfali, E. (2022) · Jundishapur Journal of Microbiology · doi:10.5812/jjm-131046 · Cited by 13
“At least 2-fold increased overexpression was observed (36).”
BackgroundGraham, D. O., Wilson, R. K., Ruma, Y. N., Keniya, M. V., Tyndall, J. D. A., & Monk, B. C. (2021) · Journal of Fungi · doi:10.3390/jof7110897 · Cited by 12
“These include the overexpression of CaERG11 and drug efflux pumps [37,38] due to gain-of-function mutations in the transcription factors (Upc2, Mrr1 and Tac1), and aneuploidy and isochromosome formation in a region of chromosome 5 which encodes Erg11 and the Tac1 transcriptional regulator that affects expression of th…”
BackgroundMethodWhat ‘Omics can tell us about antifungal adaptation
Ribeiro, G. F., Denes, E., Heaney, H., & Childers, D. S. (2021) · FEMS Yeast Research · doi:10.1093/femsyr/foab070 · Cited by 11
Efficacy of Flavonoids in Combating Fluconazole Resistant Oral Candidiasis
Srivastava, D., Yadav, A., Naqvi, S., Awasthi, H., & Fatima, Z. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220324140257 · Cited by 11
Clorgyline Analogs Synergize with Azoles against Drug Efflux in Candida auris
Toepfer, S., Lackner, M., Keniya, M. V., Zenz, L.-M., Friemert, M., Bracher, F., & Monk, B. C. (2023) · Journal of Fungi · doi:10.3390/jof9060663 · Cited by 11
“albicans, leading to Erg11 overexpression and FLC resistance [26].”
BackgroundFungal diversity and drug susceptibility of the oral mycobiome of domestic dogs
Esquivel, B. D., Salcido, E. M. R., Schweiker, A. M., Holder, B. L., KuKanich, B. K., KuKanich, K. S., & White, T. C. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1281712 · Cited by 12
Mechanisms of Drug Resistance in Fungi and Their Significance in Biofilms
Prasad, R., Shah, A. H., & Dhamgaye, S. (2014) · Springer series on biofilms · doi:10.1007/978-3-642-53833-9_4 · Cited by 14
Accoceberry, I., Rougeron, A., Biteau, N., Chevrel, P., Fitton‐Ouhabi, V., & Noël, T. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01483-17 · Cited by 12
Zeitoun, H., Salem, R. A., Guink, N. E., Tolba, N. S., & Mohamed, N. M. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03512-0 · Cited by 11
Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs
Schmidlin, K., Apodaca, S., Newell, D., Sastokas, A., Kinsler, G., & Geiler‐Samerotte, K. (2024) · eLife · doi:10.7554/elife.94144 · Cited by 18
“…nucleotide mutations in either PDR1 or PDR3, and a few with mutations in SUR1 or UPC2, genes which have all been shown to contribute to FLU resistance in previous work ( Flowers et al., 2012 ; Tanaka and Tani, 2018 ; Uemura and Moriguchi, 2022 ; Vasicek et al., 2014 ; Vu and Moye-Rowley, 2022 ).”
Hsp90-Mediated Multi-Drug Resistance in DNA Polymerase-Defective Strains of Candida albicans
Utkalaja, B. G., Sahu, S. R., Parida, S. S., & Acharya, N. (2024) · Journal of Fungi · doi:10.3390/jof10030222 · Cited by 9
Wang, H., Wang, Y., Wang, J., Wang, M., Yin, Y., Chen, Y., Liu, Z., Li, G., & Ma, Z. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2899-1 · Cited by 9
“When ergosterol is plentiful, Upc2 binds to ergosterol and predominantly localizes to the cytoplasm because the lipid-binding domain masks the NLS (Flowers et al., 2012; Tan et al., 2022; Yang et al., 2015).”
Štefánek, M., Garaiová, M., Valček, A., Jordao, L., & Bujdáková, H. (2023) · Cells · doi:10.3390/cells12121579 · Cited by 7
Arrieta-Aguirre, I., Menéndez-Manjón, P., Carrano, G., Díez, A., Fernandez-de-Larrinoa, Í., & Moragues, M. D. (2023) · Journal of Fungi · doi:10.3390/jof9121145 · Cited by 7
“Furthermore, gain-of-function (GOF) mutations in TAC1 , UPC2 , MRR1 [14–16], and, more recently, MRR2 genes [17], transcription regulators of some of the genes mentioned above lead to constitutive overexpression, resulting in increased resistance.”
BackgroundInfluentialMechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch130 · Cited by 9
Tournu, H., Butts, A., & Palmer, G. E. (2019) · mSphere · doi:10.1128/msphere.00192-19 · Cited by 6
“ACT1 was used to normalize the data, and expression levels of each target gene were calculated using the threshold cycle (ΔΔCT) method as previously described (35).”
Morschhäuser, J. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012643 · Cited by 9
“GOF mutations in UPC2 , either heterozygous or homozygous, have subsequently been found in many other ERG11 -overexpressing C . albicans isolates and shown to confer increased fluconazole resistance [85,89–91], although ERG11 overexpression can also be achieved by gene amplification [92].”
BackgroundSelf-citationRogers, P. D. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01143-y · Cited by 5
Self-citationGómez‐Raja, J., & Larriba, G. (2013) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2013.04.007 · Cited by 6
“albicans (Bruzual and Kumamoto, 2011; Dunkel and Morschhauser, 2011; Flowers et al., 2012; Gomez-Raja et al., 2008; Legrand et al., 2007;Mishra et al., 2011),we selected three independent DNA regions, theHIS4 and the EST2ORF, and the CEN4 region and determined mutational changes by direct DNA sequencing of the corresp…”
BackgroundSchmidlin, K., Apodaca, S., Newell, D., Sastokas, A., Kinsler, G., & Geiler‐Samerotte, K. (2024) · eLife · doi:10.7554/elife.94144.1 · Cited by 7
Saha, D., Gregor, J. B., Hoda, S., Eastman, K. E., Gutierrez-Schultz, V. A., Navarrete, M., Wisecaver, J. H., & Briggs, S. D. (2024) · mSphere · doi:10.1128/msphere.00524-24 · Cited by 4
Kumar, A., Francis, A., Hans, S., & Thakur, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_8 · Cited by 7
Birštonas, L., Hortschansky, P., Bauer, I., Alcanzo, E. M., Kühbacher, A., Mertens, B., Müller, C., Brakhage, A. A., & Gsaller, F. (2025) · mBio · doi:10.1128/mbio.01854-25 · Cited by 5
Hiyama, Y., Sato, T., Takahashi, S., Yamamoto, S., Ogasawara, N., Masumori, N., & Yokota, S. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115556 · Cited by 9
Jahanshiri, Z., Manifar, S., & Hatami, F. (2023) · Iranian Journal of Microbiology · doi:10.18502/ijm.v15i1.11933 · Cited by 9
Mechanisms of antifungal resistance
Delgado, J., Núñez, F., Bermúdez, E., & Asensio, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00156-8 · Cited by 7
The Ins and Outs of Azole Antifungal Drug Resistance: Molecular Mechanisms of Transport
Zavřel, M., Esquivel, B. D., & White, T. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0667-3_29-1 · Cited by 7
Mathematical Modeling of Fluconazole Resistance in the Ergosterol Pathway of Candida albicans
Yu, P. K., Espiritu, L. M., & Lao, A. R. (2022) · mSystems · doi:10.1128/msystems.00691-22 · Cited by 5
“On the other hand, an overexpression of the ERG11 gene is a known azole resistance mechanism [25].”
BackgroundZhou, X., Hilk, A. L., Solis, N. V., Hogan, B. M., Bierbaum, T. A., Filler, S. G., Burrack, L. S., & Selmecki, A. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.06.583770 · Cited by 5
Yu, P., Ye, S., Zhou, M., Zhang, L., Zhang, Z., Sun, X., Li, S., & Hu, C. (2024) · mSphere · doi:10.1128/msphere.00703-24 · Cited by 5
“Gain-of-function mutations in Upc2p are frequently implicated in the overexpression of erg11 , which is a key driver of azole resistance observed in clinical isolates (22).”
Ramírez-Zavala, B., Krüger, I., Schwanfelder, S., Barker, K. S., Rogers, P. D., & Morschhäuser, J. (2024) · mSphere · doi:10.1128/msphere.00270-24 · Cited by 6
Self-citationAzoles Used in Agriculture as Possible Cause of Azole-Resistance in Clinical Candida Isolates
Kaur, H., Yadav, A., Wadhwa, K., Jain, K., & Ghorai, S. M. (2021) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/2884 · Cited by 7
The small GTPase Rhb1 is involved in the cell response to fluconazole inCandida albicans
Chen, Y., Yeh, Y.-C., Chen, H.-F., Chen, R.-C., Lin, G.-Y., Chen, Y.-T., & Lan, C. (2019) · FEMS Yeast Research · doi:10.1093/femsyr/foz005 · Cited by 5
Shi, H., Chang, W., Zhang, M., & Lou, H. (2019) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(19)30023-8 · Cited by 7
Evolution of antimicrobial drug resistance in human pathogenic fungi
Mir, M. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96127-1.00009-7 · Cited by 5
Vu, B. G., Stamnes, M. A., Li, Y., Rogers, P. D., & Moye-Rowley, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.07.443069 · Cited by 4
Self-citationHarrison, M., Rinker, D. C., LaBella, A. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.09.653161 · Cited by 4
Voropaev, A. D., Yekaterinchev, D. A., Urban, Y. N., Zverev, V. V., Nesvizhsky, Y. V., Александровна, В. Е., Likhanskaya, E. I., Afanasiev, M. S., & Afanasiev, S. S. (2022) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-ccm-1931 · Cited by 4
Do mitochondria use efflux pumps to protect their ribosomes from antibiotics?
Islam, M. D., Harrison, B. D., Li, J. J.-Y., Mcloughlin, A. G., & Court, D. A. (2023) · Microbiology · doi:10.1099/mic.0.001272 · Cited by 5
Hervay, N. T., Bencova, A., Valachovič, M., Morvová, M., & Gbelská, Y. (2020) · Yeast · doi:10.1002/yea.3527 · Cited by 3
“…is up-regulated in Klupc2Δ mutant Several reports in C. albicans showed that CaUpc2p positively regulates the expression of MDR1 gene, encoding a multidrug transporter of the major facilitator superfamily that exports azoles (Dunkel et al., 2008; Flowers et al., 2012; Znaidi et al., 2008).”
BackgroundResistance mechanisms of Cryptococcus spp. and plant compounds as tools to combat them
da Silva, S. P., da Costa, C. B. L., da Silva, J. D. F., Alves, R. R. D. V., Silva, G. A. D. S., de Freitas, A. F. S., Guedes, C. C. D. S., Marinho, A. D. O., Paiva, P. M. G., & Napoleão, T. H. (2021) · Research Society and Development · doi:10.33448/rsd-v10i2.12819 · Cited by 5
“…and other drug transporters, changes in the drug target and/or implementation of alternative metabolic pathways (Figure 1) (Sionov et al., 2009; Flowers et al., 2012; Lockhart et al., 2017; Healey et al., 2018; Chowdhary et al., 2018; Stone et al., 2019). common mechanism of microbial…”
BackgroundGómez‐Raja, J., & Larriba, G. (2013) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2013.09.010 · Cited by 3
The Evolution of Microbial Defence Systems Against Antimicrobial Agents
Madhav, A., Will, R. C., & Mutreja, A. (2020) · Springer eBooks · doi:10.1007/978-981-15-3658-8_1 · Cited by 4
Taylor, M. B., Skophammer, R. G., Warwick, A. R., Boyer, J. M., Students, Y., Walson, M., Large, C. R. L., Hickey, A. S.-M., Rowley, P. A., & Dunham, M. J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.02.442375 · Cited by 3
Zhou, X., Hilk, A. L., Solis, N. V., Scott, N. E., Zajac, C., Filler, S. G., & Selmecki, A. M. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003631 · Cited by 2
Day, A. W., & Kumamoto, C. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298724 · Cited by 4
“Four hour ethanol survival of the SC5314 WT strain [31] and homozygous UPC2 G648D mutant strain was determined as described previously.”
Ollinger, T. L., Żarnowski, R., Parker, J. E., Kelly, S. L., Andes, D. R., Stamnes, M. A., & Krysan, D. J. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01294-24 · Cited by 2
“Gain-of-function UPC2 mutants in C. albicans (7) and S. cerevisiae (23) cause reduced susceptibility to azole drugs.”
Lipidomics Approaches: Applied to the Study of Pathogenesis in Candida Species
Singh, A., Khandelwal, N., & Prasad, R. (2019) · Progress in molecular and subcellular biology · doi:10.1007/978-3-030-13035-0_8 · Cited by 2
Fungal Drug Resistance: Azoles
Lopez-Ribot, J. L., Wiederhold, N. P., & Patterson, T. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_27 · Cited by 3
Choi, M. J., Kwon, Y. J., Byun, S. A., Kim, M., Lee, W. G., Lee, J., Yong, D., Chang, C. L., Won, E. J., Kim, S. H., et al. (2023) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.43.6.614 · Cited by 4
“CDR1/CDR2 and MDR1 overexpression can be explained by TAC1 and MRR1 GoF mutations, but ERG11 overexpression is not always associated with UPC2 GoF mutations, suggesting the existence of additional regulators [21].”
BackgroundShrivastava, M., Kouyoumdjian, G. S., Kirbizakis, E., Ruiz, D., Henry, M., Vincent, A. T., Sellam, A., & Whiteway, M. S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.24.524502 · Cited by 2
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0134 · Cited by 2
Fattouh, N., Hdayed, D., Hijazi, A., Tokajian, S. T., & Khalaf, R. A. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.07.010 · Cited by 4
Cytrynbaum, E. G., & McClean, M. N. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115740 · Cited by 1
The molecular basis of intrinsic resistance to azoles in Rhizopus arrhizus
Lackner, M., Toepfer, S., Keniya, M. V., Lax, C., Nicolás, F. E., Garre, V., Müller, C., Rosam, K., Zenz, L.-M., Cesarini, L., et al. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01337-25 · Cited by 2
Harrison, M., Rinker, D. C., LaBella, A. L., Opulente, D. A., Wolters, J. F., Zhou, X., Shen, X., Groenewald, M., Hittinger, C. T., & Rokas, A. (2026) · PLoS Genetics · doi:10.1371/journal.pgen.1012091 · Cited by 8
“Resistance to azoles can also arise through regulatory changes that may either increase the expression of Erg11 (e.g., via Upc2 [23,24], or that upregulate cellular efflux pathways (e.g., ATP-binding cassette family and the major facilitator superfamily [17,20]) to actively remove the drugs.”
Fungal Antimicrobial Resistance: Mechanisms, Drivers, and Global Clinical Burden
Baral, B. (2026) · ChemFoodChem · doi:10.1002/cfch.70026 · Cited by 2
Fine-Scale Chromosomal Changes in Fungal Fitness
Fischer, D., Hube, B., & Brunke, S. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0179-9 · Cited by 1
Carpenter, R. E. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.117005 · Cited by 5
Use of Novel Tools to Probe Drug Resistance in Fungi
Zhao, Y., & Perlin, D. S. (2017) · Springer eBooks · doi:10.1007/978-1-4939-0694-9_21 · Cited by 1
Metadata
- Authors
- Flowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D.
- Affiliations
- University of Tennessee Health Science Center (US)
- Medical Diagnostic Laboratories (United States) (US)
- University of Würzburg (DE)
- ORCID
- Venue
- Eukaryotic Cell
- Publisher
- American Society for Microbiology
- Published
- 2012-10
- Volume
- 11
- Issue
- 10
- Pages
- 1289-1299
- ISSN
- 1535-9778 (ISSN-L)
- 1535-9786
- PMC
- PMC3485914
- OpenAlex
- W2169755129
- Cited by
- 239
- References
- 32
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 25 · 2023: 22 · 2022: 19 · 2021: 22 · 2020: 21 · 2019: 23 · 2018: 11 · 2017: 20 · 2016: 9 · 2015: 14 · 2014: 16 · 2013: 11
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Eukaryotic Cell (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI058145)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, UPC2, ERG11, fluconazole resistance, azole resistance, gain-of-function mutations, zinc cluster transcription factors, ergosterol biosynthesis, transcriptional regulation, clinical isolates, antifungal resistance
- MeSH terms
- Antifungal Agents, Candida albicans, Cytochrome P-450 Enzyme System, Ergosterol, Fungal Proteins, Transcription Factors, Transcription, Genetic, Fluconazole, Up-Regulation, Genome, Fungal, Mutation, Missense, ATP Binding Cassette Transporter, Subfamily B, Member 1, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-02, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-02 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.